Dimethyl fumarate Teva यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

dimethyl fumarate teva

teva gmbh - dimethyl fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Dimethyl fumarate Accord यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

dimethyl fumarate accord

accord healthcare s.l.u. - dimethyl fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Tyruko यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Yesafili यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

yesafili

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmoloģiskie līdzekļi - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Sorafenib Sandoz 400 mg apvalkotās tabletes लातविया - लातवियाई - Zāļu valsts aģentūra

sorafenib sandoz 400 mg apvalkotās tabletes

sandoz d.d., slovenia - sorafenibs - apvalkotā tablete - 400 mg

Opexa 20 mg mutē disperģējamās tabletes लातविया - लातवियाई - Zāļu valsts aģentūra

opexa 20 mg mutē disperģējamās tabletes

menarini international operations luxembourg s.a., luxembourg - bilastīns - mutē disperģējamā tablete - 20 mg

Opexa 20 mg mutē disperģējamās tabletes लातविया - लातवियाई - Zāļu valsts aģentūra

opexa 20 mg mutē disperģējamās tabletes

menarini international operations luxembourg s.a., luxembourg - bilastīns - mutē disperģējamā tablete - 20 mg

Olmesartan medoxomil/Amlodipine Sandoz 40 mg/10 mg apvalkotās tabletes लातविया - लातवियाई - Zāļu valsts aģentūra

olmesartan medoxomil/amlodipine sandoz 40 mg/10 mg apvalkotās tabletes

sandoz d.d., slovenia - olmesartanum medoxomilum, amlodipinum - apvalkotā tablete - 40 mg/10 mg

Olmesartan medoxomil/Amlodipine Sandoz 40 mg/5 mg apvalkotās tabletes लातविया - लातवियाई - Zāļu valsts aģentūra

olmesartan medoxomil/amlodipine sandoz 40 mg/5 mg apvalkotās tabletes

sandoz d.d., slovenia - olmesartanum medoxomilum, amlodipinum - apvalkotā tablete - 40 mg/5 mg

Olmesartan medoxomil/Amlodipine Sandoz 20 mg/5 mg apvalkotās tabletes लातविया - लातवियाई - Zāļu valsts aģentūra

olmesartan medoxomil/amlodipine sandoz 20 mg/5 mg apvalkotās tabletes

sandoz d.d., slovenia - olmesartanum medoxomilum, amlodipinum - apvalkotā tablete - 20 mg/5 mg